References:
1. Daniels NF, Ridwan R. Acute kidney injury precipitating myocardial injury in a young male with COVID-19. Intern Med J. 2021;51(5):816-817. https://doi.org/https://doi.org/10.1111/imj.14977
2. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care. 2014;20(6):588-595. https://doi.org/10.1097/MCC.0000000000000153
3. de Pablo R, Monserrat J, Prieto A, Alvarez-Mon M. Role of circulating lymphocytes in patients with sepsis. Biomed Res Int. 2014;2014(671087. https://doi.org/10.1155/2014/671087
4. Smyth SS, Reis ED, Zhang W, et al. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation. 2001;103(20):2501-2507. https://doi.org/10.1161/01.cir.103.20.2501
5. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819-835. https://doi.org/10.1084/jem.20112322
6. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res. 2020;127(4):571-587. https://doi.org/doi:10.1161/CIRCRESAHA.120.317447
7. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374. https://doi.org/10.1038/s41577-020-0311-8
8. Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. Front Immunol. 2021;12(952). https://doi.org/10.3389/fimmu.2021.652470
9. Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842-844. https://doi.org/10.1038/s41591-020-0901-9
10. Hermann R, Siegmund W, Giessmann T, et al. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide. J Clin Pharmacol. 2007;47(8):1005-1013. https://doi.org/10.1177/0091270007300950
11. Salvesen ØNU, Davidsen JR, Pottegård A, Henriksen DP. Roflumilast Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study. Basic Clin Pharmacol Toxicol. 2018;123(3):314-319. https://doi.org/https://doi.org/10.1111/bcpt.13014
12. Bonato JM, Meyer E, de Mendonça PSB, et al. Roflumilast protects against spatial memory impairments and exerts anti-inflammatory effects after transient global cerebral ischemia. Eur J Neurosci. 2021;53(4):1171-1188. https://doi.org/10.1111/ejn.15089
13. Kwak HJ, Song JS, Heo JY, et al. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther. 2005;315(3):1188-1195. https://doi.org/10.1124/jpet.105.092056
14. Cortijo J, Iranzo A, Milara X, et al. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol. 2009;156(3):534-544. https://doi.org/10.1111/j.1476-5381.2008.00041.x
15. Buenestado A, Grassin-Delyle S, Guitard F, et al. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2012;165(6):1877-1890. https://doi.org/10.1111/j.1476-5381.2011.01667.x
16. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol. 1999;56(1):170-174. https://doi.org/10.1124/mol.56.1.170
17. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A. 2002;99(11):7628-7633. https://doi.org/10.1073/pnas.122041599
18. Zheng XY, Chen JC, Xie QM, Chen JQ, Tang HF. Anti‑inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B. Mol Med Rep. 2019;19(3):1728-1738. https://doi.org/10.3892/mmr.2019.9802
19. Souto FO, Alves-Filho JC, Turato WM, et al. Essential role of CCR2 in neutrophil tissue infiltration and multiple organ dysfunction in sepsis. Am J Respir Crit Care Med. 2011;183(2):234-242. https://doi.org/10.1164/rccm.201003-0416OC
20. Totani L, Amore C, Di Santo A, et al. Roflumilast inhibits leukocyte–platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes. J Thromb Haemost. 2016;14(1):191-204. https://doi.org/https://doi.org/10.1111/jth.13173